Royalty Pharma plc (MUN:RPD)

Germany · Delayed Price · Currency is EUR

33.60

-0.24 (-0.71%)

At close: Nov 21, 2025

Revenue

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	2014 - 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2014 - 2020
Cystic Fibrosis Franchise Revenue	819.92M	826.21M	Log In	Log In	Log In	Upgrade
Evrysdi Revenue	213.41M	224.43M	Log In	Log In	Log In	Upgrade
Trelegy Revenue	149.91M	146.92M	Log In	Log In	Log In	Upgrade
Tremfya Revenue	149.47M	147.14M	Log In	Log In	Log In	Upgrade
Tysabri Revenue	120.29M	124.82M	Log In	Log In	Log In	Upgrade
Imbruvica Revenue	-	131.09M	Log In	Log In	Log In	Upgrade
Xtandi Revenue	-	-	Log In	Log In	Log In	Upgrade
Promacta Revenue	-	-	Log In	Log In	Log In	Upgrade
Other Products Revenue	636.85M	548.82M	Log In	Log In	Log In	Upgrade
Total Income from Financial Royalty Assets	2.23B	2.15B	Log In	Log In	Log In	Upgrade
Revenue from Intangible Royalty Assets	-	-	Log In	Log In	Log In	Upgrade
Other Royalty Income	-	-	Log In	Log In	Log In	Upgrade
Other Royalty Income and Revenue	119.28M	114.15M	Log In	Log In	Log In	Upgrade
Revenue (Other)	-213.41M	-224.43M	Log In	Log In	Log In	Upgrade
Revenue (Total)	2.35B	2.26B	Log In	Log In	Log In	Upgrade

Key Performance Indicators

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	2014 - 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2014 - 2020
Portfolio Receipts	3.12B	2.80B	Log In	Log In	Log In	Upgrade

Updated Sep 30, 2025. Data Source: Fiscal.ai.